FINWIRES · TerminalLIVE
FINWIRES

Medibank Private Reports Policyholder Growth in Nine Months to March 31, Maintains Outlook

By

-- Medibank Private (ASX:MPL) reported policyholder growth of 22,400 in its resident private health insurance business in the nine months to March 31, up 25% from the same period a year earlier, according to a Tuesday filing with the Australian bourse.

The company said the resident private health insurance industry has become more competitive in recent months, with data showing consumers increasingly prioritizing value and some participants resorting to price-led customer propositions.

"While no new material trends have emerged in 2026, Medibank will continue to monitor utilization given historic behavior and competitor activity as we remain disciplined," it said.

Medibank maintained its fiscal 2026 guidance, saying it does not expect global events and volatility to have a direct impact on its businesses.

The company's main financial exposure is through its investment portfolio, which includes about AU$188 million of investments in equities, and through movements in Australia's cash rate where it flagged a roughly AU$7 million annual impact to investment income.

Related Articles

Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX
Asia

ALS Flags Unauthorized Access to Its IT Systems

ALS (ASX:ALQ) reported a cyber incident involving unauthorized third-party access to some of its information technology (IT) systems, temporarily disrupting parts of its operations, according to a Tuesday Australian bourse filing.The company, with support from external cybersecurity specialists, has implemented containment measures in line with incident response procedures, restoring most operations while continuing targeted remediation in affected areas, per the filing.The company has informed the Australian Cyber Security Center and is investigating the full extent of the breach and its potential data impact, the filing added.

$ASX:ALQ
Asia

Dexus Secures JV With Boral for Major Ravenhall Logistics Precinct in Melbourne

Dexus (ASX:DXS) has entered a joint venture (JV) with Boral (ASX:BLD) to develop a large-scale logistics precinct in Ravenhall, Melbourne's western corridor, spanning 630 hectares and targeting up to 2.5 million square meters of lettable space, subject to rezoning and regulatory approvals, according to a Tuesday Australian bourse filing.The JV structure gives the company and other capital partners a combined 50% stake, while Boral retains the remaining 50%, with the project developed in staged superlots and supported by substantial third-party capital to enhance capital efficiency, per the filing.The company will oversee rezoning, development, and management, with limited short-term financial impact, while management fees will begin as each stage of investment is completed, the filing added.

$ASX:BLD$ASX:DXS